The next frontier in clinical trials: navigating multi-disease research with GLP-1s
As GLP-1s redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways
Read More
Section: Research
GSK to acquire biopharma Nuvalent for $10.6bn
Two of Nuvalent’s NSCLC therapies have received FDA Breakthrough Therapy and Orphan Drug Designations
Read More
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology
Read More
Alnylam and Inceptive agree on $2bn AI collaboration
The deal will assist accelerate the discovery of RNAi therapeutics
Read More
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
The drug showed improvements in overall survival and progression-free survival in two cancers
Read More